Smith+Nephew has received FDA clearance for the Aetos Stemless shoulder implant, enhancing its upper extremity portfolio. This innovation caters to the growing demand for efficient, anatomical total shoulder replacements with minimal operating room requirements.
Key Features of Aetos Stemless
- Enhanced Fixation: Includes an inlay collar, cruciate fins, and porous titanium coating to encourage biological fixation and maximize stability.
- Streamlined Design: Supports metaphyseal fixation with an efficient procedure setup.
- Surgical Flexibility: Allows for seamless convertibility from Stemless to the Meta Stem within the Aetos system.
This latest addition builds on the company’s U.S. launch of the Aetos shoulder system, which began earlier this year. Initially cleared by the FDA in June 2023, the system is designed to restore shoulder range of motion while minimizing arthritic pain.
A Leap Forward in Shoulder Arthroplasty
Craig Gaffin, President of Global Orthopaedics at Smith+Nephew, highlighted the significance of the new implant:
“Aetos Stemless represents a significant advancement in shoulder arthroplasty, underscoring our commitment to superior patient outcomes and driving progress in orthopaedic surgery. With Aetos Stemless, we can further personalize surgery, providing options that help surgeons give patients the best chance for recovery and a return to living their ‘Life Unlimited.’”
By expanding its Aetos portfolio, Smith+Nephew reinforces its dedication to advancing orthopaedic care with patient-focused solutions.
Follow MEDWIRE.AI for the latest FDA advancements in orthopaedic surgery and medical device advancements.
